Sprint Bioscience AB (OSTO:SPRINT) Ending Cash Position: kr108.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
22 GF Score
Price kr3.60
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Ending Cash Position?

Sprint Bioscience AB OSTO:SPRINT -3.49% 22 Ending Cash Position is kr108.3 Mil as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Sprint Bioscience AB's Ending Cash Position for the quarter that ended in Mar. 2026 was kr108.3 Mil.

Sprint Bioscience AB's quarterly Ending Cash Position increased from Sep. 2025 (kr10.9 Mil) to Dec. 2025 (kr126.7 Mil) but then declined from Dec. 2025 (kr126.7 Mil) to Mar. 2026 (kr108.3 Mil).

Sprint Bioscience AB's annual Ending Cash Position declined from Dec. 2023 (kr49.9 Mil) to Dec. 2024 (kr25.1 Mil) but then increased from Dec. 2024 (kr25.1 Mil) to Dec. 2025 (kr126.7 Mil).

Sprint Bioscience AB Ending Cash Position Related Terms

Sprint Bioscience AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Ending Cash Position Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.64 0.00 49.93 25.06 126.70

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.79 24.66 10.95 126.70 108.33
OSTO:SPRINT
22GF Score
Sprint Bioscience AB OSTO:SPRINT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sprint Bioscience AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=25.056+101.648
=126.7

Sprint Bioscience AB's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=126.704+-18.375
=108.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr108.3 Mil mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Ending Cash Position of kr108.3 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Ending Cash Position too high?
Sprint Bioscience AB's current Ending Cash Position is kr108.3 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Ending Cash Position compare to VRTX and REGN?
Sprint Bioscience AB's Ending Cash Position of kr108.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Ending Cash Position is kr108.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (OSTO:SPRINT) has a current Ending Cash Position of kr108.3 Mil. The current Ending Cash Position is kr108.3 Mil. Sprint Bioscience AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Ending Cash Position is kr108.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
22GF Score

Get the complete analysis for OSTO:SPRINT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.60
Price